TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced James A. Bianco, M.D., President and Chief...

Read More